M&A / Deals Merck Chopped $1B Off Terns’ Offer After Seeing Updated Leukemia Data BioSpaceAnother bidder, which remains unidentified, dropped out of the bidding process.M&A / DealsHematologyRead full story pharminent April 8, 2026 (Last updated: April 8, 2026) BioSpace Another bidder, which remains unidentified, dropped out of the bidding process. M&A / DealsHematologyRead full story Post navigation Previous: List Price Reductions Will Deflate the Gross-to-Net Bubble-and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)Next: Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
